Endologix, Inc. (ELGX) financial statements (2022 and earlier)
Company profile
| Business Address |
2 MUSICK IRVINE, CA 92618 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 3841 - Surgical and Medical Instruments and Apparatus (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 6/30/2020 Q2 | 3/31/2020 Q1 | 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 18,496 | 41,560 | 46,587 | 50,943 | 9,696 | |||
| Cash and cash equivalents | 18,496 | 41,560 | 46,587 | 50,943 | 9,696 | |||
| Restricted cash and investments | 1,200 | 1,200 | 1,200 | 1,200 | 1,200 | |||
| Receivables | 11,362 | 22,674 | 21,887 | 22,258 | 26,328 | |||
| Inventory, net of allowances, customer advances and progress billings | 25,908 | 26,405 | 30,877 | 30,747 | 30,202 | |||
| Inventory | 25,908 | 26,405 | 30,877 | 30,747 | 30,202 | |||
| Other current assets | 4,441 | 1,864 | 2,058 | 2,270 | 2,535 | |||
| Total current assets: | 61,407 | 93,703 | 102,609 | 107,418 | 69,961 | |||
| Noncurrent Assets | ||||||||
| Operating lease, right-of-use asset | 5,644 | 5,768 | 5,660 | 5,728 | ||||
| Property, plant and equipment | 11,838 | 13,152 | 13,691 | 14,495 | 15,236 | |||
| Intangible assets, net (including goodwill) | 191,864 | 193,417 | 194,264 | 195,278 | 196,117 | |||
| Goodwill | 120,816 | 120,814 | 120,770 | 120,837 | 120,815 | |||
| Intangible assets, net (excluding goodwill) | 71,048 | 72,603 | 73,494 | 74,441 | 75,302 | |||
| Other noncurrent assets | 662 | 1,124 | 1,293 | 1,372 | 2,392 | |||
| Other undisclosed noncurrent assets | 5,787 | |||||||
| Total noncurrent assets: | 210,008 | 213,461 | 214,908 | 216,873 | 219,532 | |||
| TOTAL ASSETS: | 271,415 | 307,164 | 317,517 | 324,291 | 289,493 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 36,911 | 45,187 | 46,302 | 42,531 | 44,153 | |||
| Accounts payable | 8,837 | 14,024 | 11,779 | 12,454 | 14,923 | |||
| Accrued liabilities | 15,084 | 12,931 | 15,791 | 16,241 | 16,057 | |||
| Employee-related liabilities | 12,990 | 18,232 | 18,732 | 13,836 | 13,173 | |||
| Debt | 192,687 | |||||||
| Other undisclosed current liabilities | 10,606 | |||||||
| Total current liabilities: | 229,598 | 55,793 | 46,302 | 42,531 | 44,153 | |||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 11,127 | 183,681 | 176,993 | 165,024 | 203,482 | |||
| Long-term debt, excluding current maturities | 172,060 | 176,993 | 165,024 | 203,482 | ||||
| Operating lease, liability | 11,127 | 11,621 | ||||||
| Liabilities, other than long-term debt | 2,273 | 2,894 | 15,325 | 16,588 | 16,293 | |||
| Accounts payable and accrued liabilities | 11,640 | 11,812 | 11,976 | |||||
| Deferred income tax liabilities | 150 | 150 | 150 | 150 | ||||
| Other liabilities | 1,823 | 2,244 | 2,235 | 2,326 | 2,317 | |||
| Business combination, contingent consideration, liability | 300 | 500 | 1,300 | 2,300 | 2,000 | |||
| Other undisclosed noncurrent liabilities | 940 | 9,112 | 28,072 | 6,185 | ||||
| Total noncurrent liabilities: | 13,400 | 187,515 | 201,430 | 209,684 | 225,960 | |||
| Total liabilities: | 242,998 | 243,308 | 247,732 | 252,215 | 270,113 | |||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | 28,417 | 63,856 | 69,785 | 72,076 | 19,380 | |||
| Common stock | 19 | 18 | 18 | 17 | 10 | |||
| Treasury stock, value | (4,278) | (4,235) | (4,154) | (4,120) | (4,027) | |||
| Additional paid in capital | 738,571 | 730,729 | 728,094 | 722,478 | 643,150 | |||
| Accumulated other comprehensive income | 2,786 | 1,816 | 2,469 | 2,578 | 1,990 | |||
| Accumulated deficit | (708,681) | (664,472) | (656,642) | (648,877) | (621,743) | |||
| Total stockholders' equity: | 28,417 | 63,856 | 69,785 | 72,076 | 19,380 | |||
| TOTAL LIABILITIES AND EQUITY: | 271,415 | 307,164 | 317,517 | 324,291 | 289,493 | |||
Income statement (P&L) ($ in thousands)
| 6/30/2020 Q2 | 3/31/2020 Q1 | 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 24,841 | 35,751 | 35,775 | 36,238 | 35,606 | ||
| Cost of revenue (Cost of Goods and Services Sold) | (10,688) | (13,922) | (12,701) | (13,254) | (12,407) | ||
| Gross profit: | 14,153 | 21,829 | 23,074 | 22,984 | 23,199 | ||
| Operating expenses | (31,502) | (31,687) | (33,904) | (32,851) | (35,193) | ||
| Operating loss: | (17,349) | (9,858) | (10,830) | (9,867) | (11,994) | ||
| Nonoperating income (expense) | (8,698) | 798 | 2,784 | (20,520) | (9,995) | ||
| Interest and debt expense | (10,863) | (8,527) | (11,756) | (8,490) | |||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 10,863 | 8,527 | 11,756 | 8,490 | |||
| Loss from continuing operations before income taxes: | (26,047) | (9,060) | (8,046) | (30,387) | (21,989) | ||
| Income tax expense (benefit) | (46) | 1,230 | 281 | 3,253 | (39) | ||
| Net loss available to common stockholders, diluted: | (26,093) | (7,830) | (7,765) | (27,134) | (22,028) | ||
Comprehensive Income ($ in thousands)
| 6/30/2020 Q2 | 3/31/2020 Q1 | 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (26,093) | (7,830) | (7,765) | (27,134) | (22,028) | ||
| Other comprehensive income (loss) | 222 | (109) | 588 | ||||
| Comprehensive loss: | (25,871) | (7,830) | (7,874) | (26,546) | (22,028) | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (653) | (598) | |||||
| Comprehensive loss, net of tax, attributable to parent: | (25,871) | (8,483) | (7,874) | (26,546) | (22,626) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.